Delta-Fly Pharma, Inc. Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927
TOKUSHIMA, Japan--(BUSINESS WIRE)--Nov 26, 2019--
Delta-Fly Pharma, Inc. (TOKYO: 4598) announces that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927.
DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed Acute Myelogenous Leukemia. A Phase 3 clinical study at MD Anderson Cancer Center in Texas, USA and other sites in the USA is underway.
Two patients at UT Southwestern Medical Center in Texas and Banner MD Anderson Cancer Center in Arizona registered for this study in November 2019.
In addition, a Phase 1 clinical study of DFP-14927, the polymeric delivery of DFP-10917 in patients with advanced solid tumors has been initiated at MD Anderson Cancer Center.
Two patients registered for this study in October of this year and treatment is ongoing.
Delta-Fly Pharma, Inc. [TOKYO:4598]
2849 million Japanese Yen
Name and Title of Representative
Kiyoshi Eshima, PhD, President
Date of Incorporation
December 6, 2010
Description of Business
Research and development, manufacturing and marketing of pharmaceuticals
37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan
Tokyo, Beijing, Vancouver
View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005329/en/
CONTACT: Delta-Fly Pharma, Inc.
Inquiries: Yasuo Matsueda
KEYWORD: NORTH AMERICA UNITED STATES ASIA PACIFIC EUROPE JAPAN TEXAS ARIZONA
INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE
SOURCE: Delta-Fly Pharma, Inc.
Copyright Business Wire 2019.
PUB: 11/26/2019 04:13 AM/DISC: 11/26/2019 04:13 AM